Current Report Filing (8-k)
June 17 2019 - 7:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): June 17, 2019
Protalix
BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Delaware
|
|
001-33357
|
|
65-0643773
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
2
Snunit Street
|
|
|
Science
Park, POB 455
|
|
|
Carmiel,
Israel
|
|
20100
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area
code +972-4-988-9488
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
|
common stock, $0.001 par value
|
PLX
|
NYSE American
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
On June 17, 2019, the Company issued a press release announcing
the completion of enrollment in the Company’s phase III BRIGHT clinical trial of pegunigalsidase alfa (PRX
-
102)
for the treatment of Fabry disease, via intravenous (IV) infusions of 2 mg/kg administered every 4 weeks. A copy of the press
release is attached as Exhibit 99.1 to this Current Report on Form 8
-
K and is incorporated
herein by reference. PRX
-
102 is the Company’s plant cell-expressed recombinant, PEGylated,
cross
-
linked α
-
galactosidase
-
A
drug candidate.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June
17
,
2019
|
PROTALIX
BIOTHERAPEUTICS, INC.
|
|
|
|
By:
|
/s/
Moshe Manor
|
|
|
Name:
|
Moshe
Manor
|
|
|
Title:
|
President and Chief Executive Officer
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024